{"id":525519,"date":"2025-05-05T00:00:00","date_gmt":"2025-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0010-biopharma-crohns-disease-epidemiology-epidemiology-crohns-disease-mature-markets\/"},"modified":"2026-04-28T11:11:51","modified_gmt":"2026-04-28T11:11:51","slug":"epidim0010-biopharma-crohns-disease-epidemiology-epidemiology-crohns-disease-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0010-biopharma-crohns-disease-epidemiology-epidemiology-crohns-disease-mature-markets\/","title":{"rendered":"Crohn&#8217;s Disease &#8211; Epidemiology &#8211; Epidemiology &#8211; Crohn&#8217;s Disease &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of Crohn&#8217;s disease (<abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> for each country as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>, how many in each country in the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 16 <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed drug-treated (acute setting) prevalent cases.<\/li>\n<li>Diagnosed non-drug-treated (acute setting) prevalent cases.<\/li>\n<li>Diagnosed drug-treated (maintenance setting) prevalent cases.<\/li>\n<li>Diagnosed non-drug-treated (maintenance setting) prevalent cases.<\/li>\n<li>Diagnosed B1 (nonstricturing, nonfistulizing) prevalent cases.<\/li>\n<li>Diagnosed B2 (stricturing) prevalent cases.<\/li>\n<li>Diagnosed B3 (penetrating) prevalent cases.<\/li>\n<li>Diagnosed L1 (terminal ileum) prevalent cases.<\/li>\n<li>Diagnosed L2 (colonic) prevalent cases.<\/li>\n<li>Diagnosed L3 (ileocolonic) prevalent cases.<\/li>\n<li>Diagnosed prevalent cases in remission.<\/li>\n<li>Diagnosed mild <abbr title=\"Crohn's disease\">CD<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed moderate <abbr title=\"Crohn's disease\">CD<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed severe <abbr title=\"Crohn's disease\">CD<\/abbr> prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-525519","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-gastrointestinal","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525519\/revisions"}],"predecessor-version":[{"id":525777,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525519\/revisions\/525777"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=525519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}